伊潘立酮与利培酮治疗精神分裂症的安全性评价  

Safety evaluation of iloperidone and risperidone in the treatment of schizophrenia

作　　者：王宏燕[1] 韩宝杰[2] 双梅[2] 张鸿燕[2] 

机构地区：[1]太原市精神病医院精神分裂症女科,太原030045 [2]北京大学第六医院卫生部精神卫生学重点实验室,北京100191

出　　处：《中国临床药理学杂志》2015年第24期2402-2404,2407,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的评价伊潘立酮片治疗精神分裂症的安全性。方法将260例精神分裂症的患者随机分为对照组130例和试验组130例。对照组予以口服利培酮片3~6 mg·d^(-1),每日两次;试验组予以口服伊潘立酮片12~24 mg·d^(-1),每日两次。2组患者均治疗6周。治疗后,比较2组患者的不良反应发生率。结果 2组患者常见的不良反应有泌乳素升高、锥体外系反应、转氨酶升高、体重增加、心电图异常、低血压、血脂升高等,其中试验组泌乳素升高和锥体外系反应的发生率明显低于对照组(P<0.05)且试验组体重增加的幅度较对照组低。结论伊潘立酮治疗精神分裂症引起锥体外系反应、泌乳素升高、体重增加的可能性较利培酮小,安全性较好。Objective To evaluate the safety of iloperidone in the treatment of schizophrenia.Methods Two hundred and sixty patients with schizophrenia were randomly divided into control group（130 cases） and treatment group（130 cases）.Risperidone 3-6 mg·d^-1 was given to the control group,and the treatment group was poured iloperidone12-24 mg · d^-1.Both treated for 6 weeks,oral,twice a day.Compared the adverse drug reactions rate between the two groups.Results The common adverse reactions were prolactin increasing,extrapyramidal symptoms,elevated aminotransferase,weight gain,abnormal electrocardiogram,low blood pressure and high blood lipid,etc.The incidence of prolactin increasing and extrapyramidal symptoms were significantly lower in the group of iloperidone（P〈0.05）.The iloperidone group demonstrated lower weight gain increasing than risperidone.Conclusion Iloperidone has good safety in the treatment of schizophrenia with fewer extrapyramidal symptoms,prolactin increasing and weight gain.

关 键 词：伊潘立酮 利培酮 精神分裂症 安全性 

分 类 号：R971.41[医药卫生—药品] R749.3[医药卫生—药学]